The Incretin System
GLP-1 (glucagon-like peptide-1) is a 30-amino-acid peptide hormone secreted by L-cells in the distal small intestine and colon in response to food intake. It is one of two major incretin hormones (the other being GIP, glucose-dependent insulinotropic polypeptide) responsible for the "incretin effect" — the observation that oral glucose produces a significantly greater insulin response than the same amount of glucose given intravenously. Under normal physiology, GLP-1 accounts for roughly 50-70% of the total post-meal insulin secretion, making it a cornerstone of metabolic regulation.
The critical problem with endogenous GLP-1 is its extraordinarily short half-life. Within approximately 1-2 minutes of secretion, GLP-1 is cleaved and inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4), as well as neutral endopeptidase 24.11 (NEP 24.11) and renal clearance. As a result, only 10-15% of secreted GLP-1 reaches systemic circulation in its intact, active form. GLP-1 receptor agonist drugs solve this problem by mimicking the native hormone while incorporating structural modifications that resist DPP-4 degradation, extending the half-life from minutes to days.
GLP-1 Receptor Biology
The GLP-1 receptor (GLP-1R) is a class B G-protein-coupled receptor (GPCR) expressed widely throughout the body:
- Pancreatic beta cells — stimulation triggers glucose-dependent insulin secretion via the cAMP/PKA signaling cascade. Crucially, this insulin release is glucose-dependent: GLP-1R activation only enhances insulin secretion when blood glucose is elevated, which is why GLP-1 agonists carry very low risk of hypoglycemia compared to sulfonylureas or exogenous insulin
- Pancreatic alpha cells — GLP-1R activation suppresses glucagon secretion, reducing hepatic glucose output. This effect is also glucose-dependent and is lost when blood glucose drops to hypoglycemic levels, providing a built-in safety mechanism
- Gastrointestinal tract — GLP-1R activation significantly delays gastric emptying by inhibiting vagal afferent signaling to the brainstem. This slowed transit increases satiety and flattens post-meal glucose spikes. It is also the primary cause of the nausea, vomiting, and gastroparesis-like symptoms that many users experience
- Hypothalamus — GLP-1 receptors in the arcuate nucleus and paraventricular nucleus modulate appetite signaling. Activation of these receptors suppresses orexigenic (appetite-stimulating) NPY/AgRP neurons while enhancing anorexigenic (appetite-suppressing) POMC/CART neuronal activity, producing the profound appetite reduction users describe as "food noise going silent"
- Brainstem (nucleus tractus solitarius) — GLP-1R signaling here integrates visceral satiety signals and contributes to nausea and reduced food intake
- Mesolimbic reward system — this is where the story gets particularly interesting. GLP-1 receptors are expressed in the ventral tegmental area (VTA), nucleus accumbens, and prefrontal cortex — the brain's reward and motivation circuitry. Activation of GLP-1R on VTA GABA neurons modulates dopamine release, dampening the reward signal from food, alcohol, nicotine, and other addictive substances. This is the mechanism behind the emerging anti-addiction effects that have captured enormous research interest
- Heart and vasculature — GLP-1R activation in cardiomyocytes and vascular endothelium provides cardioprotective effects including reduced inflammation, improved endothelial function, and decreased atherosclerotic plaque progression. This explains the significant cardiovascular mortality reduction demonstrated in clinical trials like SELECT
How GLP-1 Agonist Drugs Resist DPP-4
Each GLP-1 agonist drug uses a different structural strategy to evade enzymatic degradation:
Exenatide (Byetta/Bydureon) is a synthetic version of exendin-4, the peptide originally isolated from Gila monster venom. Exendin-4 shares 53% amino acid sequence homology with human GLP-1 but has a naturally occurring glycine residue at position 2 (where human GLP-1 has alanine) and a unique C-terminal extension of 9 amino acids. These differences make it intrinsically resistant to DPP-4, extending its half-life to approximately 2.4 hours.
Liraglutide (Victoza/Saxenda) is 97% homologous to native human GLP-1, with a single amino acid substitution (lysine to arginine at position 34) and the attachment of a C16 palmitoyl fatty acid chain via a glutamic acid spacer at position 26. This fatty acid chain binds non-covalently to serum albumin in the bloodstream, creating a drug depot that slowly releases free liraglutide. This albumin binding extends the half-life to approximately 13 hours, enabling once-daily dosing.
Semaglutide (Ozempic/Wegovy/Rybelsus) represents a further optimization. It has two amino acid modifications compared to native GLP-1: an alpha-aminoisobutyric acid (Aib) substitution at position 8 (which directly blocks DPP-4 cleavage) and an arginine at position 34. At position 26, a C18 octadecandioic diacid is attached via a mini-PEG (polyethylene glycol) linker. This enhanced acylation provides stronger albumin binding than liraglutide's C16 chain, extending semaglutide's half-life to 165-184 hours (approximately 7 days), enabling once-weekly subcutaneous injection.
Tirzepatide (Mounjaro/Zepbound) represents the next evolutionary leap — it is a dual GIP/GLP-1 receptor agonist. Tirzepatide is a 39-amino-acid peptide based on the GIP sequence but engineered to also activate GLP-1 receptors. It incorporates two non-coded amino acid residues at positions 2 and 13 for DPP-4 resistance, and a C20 eicosanedioic fatty diacid attached via hydrophilic linkers for albumin binding. Its half-life is approximately 5 days. The dual GIP/GLP-1 agonism produces superior weight loss compared to GLP-1-only agonists: the SURMOUNT-5 trial demonstrated 20.2% body weight loss with tirzepatide versus 13.7% with semaglutide over 72 weeks.
Dulaglutide (Trulicity) takes a different approach, fusing a modified GLP-1 analogue to an Fc fragment of human IgG4 antibody. This large fusion protein resists renal clearance and has a half-life of approximately 5 days.
The Reward Pathway Connection
Perhaps the most scientifically exciting aspect of GLP-1 agonists is their effect on the brain's reward circuitry. GLP-1 receptors in the VTA are expressed on GABA interneurons that normally inhibit dopaminergic neurons. When GLP-1R agonists activate these GABA neurons, they increase inhibitory tone on the dopamine system, effectively dampening the reward response to food, alcohol, nicotine, and potentially other addictive stimuli.
Preclinical studies demonstrate that GLP-1R agonists decrease voluntary alcohol consumption in rodent models, reduce the motivation to consume alcohol, prevent relapse drinking, and blunt stress-induced alcohol seeking. In humans, a randomized clinical trial published in 2024 found that once-weekly semaglutide showed benefits in adults with alcohol use disorder. Observational cohort studies have shown a significantly reduced risk of alcohol use disorder and reduced alcohol consumption in patients receiving GLP-1R agonist therapy.
For nicotine, the mechanism involves additional pathways: GLP-1R activation of the medial habenular pathway appears to make the effects of nicotine aversive, reducing drug-taking behavior. The net effect across substances is a broad dampening of reward-driven compulsive behaviors — what patients describe as the same quieting of cravings they experience with food.
GLP-1 Agonists can be administered via Subcutaneous injection, Oral. The route of administration can influence both the onset and intensity of motivation enhancement.